After the landmark, IAEA trial confirming the potential of intra-arterially used Re 188 Lipoidol for the treatment of inoperable hepatocellular carcinoma (HCC), it was surprising to note that none of the participating centers took this work forward. To a nonnuclear physician or scientist, it would seem baffling, but we in NM are well aware of the difficulties in instituting a new radionuclide therapy procedure in our center. Lack of properly conducted trials, data or evidence; differing regulatory frameworks across countries, lack of funding agencies and no pharmaceutical support are some of the many hindrances that we in NM routinely take in our strides.
Thus, it would come as a surprise for the majority of the NM world, that there is a recent resurgence of this treatment option centered around India and spreading slowly to other Asian countries. When we at KMCH, Coimbatore started this program in 2013, we had to work hard at the labeling, dosimetry, and technical aspects with almost no one to help us after the untimely demise of Dr. Ajit Padhy.
However, we have kept working to improve all aspects of our technique and have achieved commendable results and with the untiring support and resorcefulness of Prof. Baum. Through WARMTH, which initiated this endeavor, we formed the WARMTH Rhenium project; a task force to enable other departments to start a Re based therapy program.
To give potential users a hands-on feel, as well as to get under one roof all past, present, and future users, researchers, scientists and clinicians of Re 188, the 1 Re 188 has the potential to be the workhorse of an NM therapy program, with its availability in a generator form, a strong Beta, imageable Gamma and a similar chemistry to Tc99m. With more than 70% of the world's HCC in Asia, where the vast majority of patients do not have any health insurance, it is imperative that a cost-effective palliative procedure be available. Even a country like India with a welldeveloped NM program and thousands of patients suffering from inoperable HCC, only 100-120 patients are treated a year with Y-90 radioconjugates, due to the exorbitant cost.
In comparison, just these 5 centers in India that have been started under the WARMTH Rhenium project have treated more than 100 HCC patients this year itself. In addition, we have managed to instill encouragement to the Re researchers all around the world, ranging from France, Iran, Taiwan, Macedonia, UK, Mexico, USA, Africa, Australia to South and South East Asian countries to work on various therapeutic solutions with Re 188 and that this isotope has a future. Toward this concerted effort, KMCH will be hosting again the 2 nd World Rhenium Congress at Coimbatore on August 14-15 th , 2017. Attending it would give you a holistic idea about the ease of setting up a Re based facility as well as the innumerable therapeutic options at your disposal.
As St Francis of Assissi said, we started by doing whats necessary; we are doing whats possible and then with your continued support we will be soon doing the impossible.
Rhenium 188: The Poor Man's Yttrium

